Pharma Deals Review, Vol 2007, No 86 (2007)

Font Size:  Small  Medium  Large

Shire Gains Anti-Scarring Product, Juvista®

Business Review Editor

Abstract


Shire has signed an agreement with Renovo Group for its drug candidate Juvista® (human TGFbeta3) for the prevention and reduction of scarring. The deal could worth up to US$825 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.